Mr. Andréasson, Dr. Archinard and Ms. Diaz currently serve on our remuneration and appointments committee. Dr. Archinard is the chairperson of our remuneration and appointments committee.
Currently, Sven Andreasson is administrator of Galenos. He is the former Chief Executive Officer of Isconova AB (Uppsala, Sweden), CEO of Beta-Cell NV (Brussels), Active Biotech AB (Lund, Sweden) and several companies in the Pharmacia group. He acquired extensive experience in the international biotechnology companies and in the pharmaceutical industry. Sven Andreasson received a BS degree in science and business administration and in Finance from Stockholm School of Economics and Business Administration.
Philippe Archinaud was appointed General Manager, CEO and director of Transgene on 7 December 2004, after 15 years in the BioMerieux group in different positions including management of the US subsidiary. Philippe Archinaud had served as CEO of Innogenetics N.V. since March 2000. He is a chemical engineer and received a PhD in biochemistry from the University of Lyons, with an advanced degree in the PMD management programme from the Harvard Business School.
Ms. Diaz has significant experience in the biopharmaceutical industry with broad cross-functional expertise in sales, medical affairs, marketing, new product planning, portfolio planning, strategic planning, and market access. She currently serves as Senior Vice President, Global Commercial Development at TESARO, where she focuses on development of commercialization strategies across therapeutic assets, evaluates the commercial impact of clinical development options, and assesses potential in-licensing opportunities. Prior to joining TESARO, Ms. Diaz served as Senior Vice President, Managed Markets at EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, where she developed market access strategies and tactics for reimbursement by commercial and government payers across the EMD Serono portfolio. Previously, Ms. Diaz also held the positions of Senior Vice President, Head of Oncology Commercial, U.S. and Vice President, Oncology Marketing at EMD Serono, where she oversaw the commercial pre-launch efforts for EMD Serono’s oncology products. Ms. Diaz has held executive, management and/or line positions at other leading companies including Amylin Pharmaceuticals, Cancervax Corporation, Biogen Idec, Pfizer, and Parke-Davis Pharmaceuticals. Ms. Diaz graduated cum laude with a Bachelor of Science from Florida State University. She has also attended executive education programs at the London School of Business and Finance, University of Michigan School of Business, China Europe International Business School (Shanghai, China), Stanford University School of Business and INSEAD (Fontainebleau, France).